ORCID Profile
0000-0003-3410-0862
Current Organisations
Cold Regions Research and Engineering Laboratory
,
GHU Paris Psychiatry & Neurosciences
,
Université Paris Descartes
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 11-2020
Publisher: Elsevier BV
Date: 2019
Publisher: IOP Publishing
Date: 21-04-2023
Abstract: Understanding how soil microbes respond to permafrost thaw is critical to predicting the implications of climate change for soil processes. However, our knowledge of microbial responses to warming is mainly based on laboratory thaw experiments, and field s ling in warmer months when sites are more accessible. In this study, we s led a depth profile through seasonally thawed active layer and permafrost in the Imnavait Creek Watershed, Alaska, USA over the growing season from summer to late fall. Amplicon sequencing showed that bacterial and fungal communities differed in composition across both s ling depths and s ling months. Surface communities were most variable while those from the deepest s les, which remained frozen throughout our s ling period, showed little to no variation over time. However, community variation was not explained by trace metal concentrations, soil nutrient content, pH, or soil condition (frozen/thawed), except insofar as those measurements were correlated with depth. Our results highlight the importance of collecting s les at multiple times throughout the year to capture temporal variation, and suggest that data from across the annual freeze-thaw cycle might help predict microbial responses to permafrost thaw.
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 08-2017
DOI: 10.1161/STROKEAHA.116.012992
Abstract: We assessed whether the presence, number, and distribution of cerebral microbleeds (CMBs) on pre-intravenous thrombolysis MRI scans of acute ischemic stroke patients are associated with an increased risk of intracerebral hemorrhage (ICH) or poor functional outcome. We performed an in idual patient data meta-analysis, including prospective and retrospective studies of acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Using multilevel mixed-effects logistic regression, we investigated associations of pre-treatment CMB presence, burden (1, 2–4, ≥5, and ), and presumed pathogenesis (cerebral amyloid angiopathy defined as strictly lobar CMBs and noncerebral amyloid angiopathy) with symptomatic ICH, parenchymal hematoma (within [parenchymal hemorrhage, PH] and remote from the ischemic area [remote parenchymal hemorrhage, PHr]), and poor 3- to 6-month functional outcome (modified Rankin score ). In 1973 patients from 8 centers, the crude prevalence of CMBs was 526 of 1973 (26.7%). A total of 77 of 1973 (3.9%) patients experienced symptomatic ICH, 210 of 1806 (11.6%) experienced PH, and 56 of 1720 (3.3%) experienced PHr. In adjusted analyses, patients with CMBs (compared with those without CMBs) had increased risk of PH (odds ratio: 1.50 95% confidence interval: 1.09–2.07 P =0.013) and PHr (odds ratio: 3.04 95% confidence interval: 1.73–5.35 P .001) but not symptomatic ICH. Both cerebral amyloid angiopathy and noncerebral amyloid angiopathy patterns of CMBs were associated with PH and PHr. Increasing CMB burden category was associated with the risk of symptomatic ICH ( P =0.014), PH ( P =0.013), and PHr ( P .00001). Five or more and CMBs independently predicted poor 3- to 6-month outcome (odds ratio: 1.85 95% confidence interval: 1.10–3.12 P =0.020 and odds ratio: 3.99 95% confidence interval: 1.55–10.22 P =0.004, respectively). Increasing CMB burden is associated with increased risk of ICH (including PHr) and poor 3- to 6-month functional outcome after intravenous thrombolysis for acute ischemic stroke.
Publisher: SAGE Publications
Date: 18-01-2016
Abstract: For the STroke Imaging Research (STIR) and VISTA-Imaging Investigators The purpose of this study was to collect precise information on the typical imaging decisions given specific clinical acute stroke scenarios. Stroke centers worldwide were surveyed regarding typical imaging used to work up representative acute stroke patients, make treatment decisions, and willingness to enroll in clinical trials. STroke Imaging Research and Virtual International Stroke Trials Archive-Imaging circulated an online survey of clinical case vignettes through its website, the websites of national professional societies from multiple countries as well as through email distribution lists from STroke Imaging Research and participating societies. Survey responders were asked to select the typical imaging work-up for each clinical vignette presented. Actual images were not presented to the survey responders. Instead, the survey then displayed several types of imaging findings offered by the imaging strategy, and the responders selected the appropriate therapy and whether to enroll into a clinical trial considering time from onset, clinical presentation, and imaging findings. A follow-up survey focusing on 6 h from onset was conducted after the release of the positive endovascular trials. We received 548 responses from 35 countries including 282 in idual centers 78% of the centers originating from Australia, Brazil, France, Germany, Spain, United Kingdom, and United States. The specific onset windows presented influenced the type of imaging work-up selected more than the clinical scenario. Magnetic Resonance Imaging usage (27–28%) was substantial, in particular for wake-up stroke. Following the release of the positive trials, selection of perfusion imaging significantly increased for imaging strategy. Usage of vascular or perfusion imaging by Computed Tomography or Magnetic Resonance Imaging beyond just parenchymal imaging was the primary work-up (62–87%) across all clinical vignettes and time windows. Perfusion imaging with Computed Tomography or Magnetic Resonance Imaging was associated with increased probability of enrollment into clinical trials for 0–3 h. Following the release of the positive endovascular trials, selection of endovascular only treatment for 6 h increased across all clinical vignettes.
Publisher: Elsevier BV
Date: 07-2019
Location: United States of America
No related grants have been discovered for Catherine Oppenheim.